The Biotech Times is the news, analysis and intelligence publication for the professionals shaping the future of biotechnology — from genomics and drug discovery to medtech, cell therapy and synthetic biology.
We cover the science, the capital, the policy, and the people behind the companies redrawing the industry. Our readers are senior operators, investors, regulators and researchers in the UK, Europe, the Gulf, the US and Asia-Pacific.
The Biotech Times is published by Disrupts Media, a specialist professional-media group, in strategic alliance with Taranis Capital.
Editorial principles
- Independent. Editorial decisions are taken independently of commercial partners, investors and the companies we cover.
- Evidence-led. We distinguish clearly between reported news, analysis and opinion.
- Professional audience. We write for practitioners — scientific literacy is assumed; so is business literacy.
Get in touch
News tips, pitches and feedback: editorial@thebiotechtimes.com